Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.37 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | PPARA | Q07869 | 2/20 | 0.37 |
| ▸ | FPR2 | P25090 | 2/20 | 0.37 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7420053 | 0.88 | KCNH2 (0.41) | PPARGPPARAKCNH2L3MBTL1CHRM2 | |
| SCHEMBL12416120 | 0.86 | CHRM2 (0.41) | KCNH2CHRM2CHRM3 | |
| SCHEMBL14534904 | 0.86 | PPARG (0.41) | PPARGPPARARAB9AMEN1ALDH1A1 | |
| SCHEMBL12416123 | 0.83 | NPC1 (0.39) | HRH3RAB9AKMT2ANPC1HPGD | |
| Trifluoroacetic Acid SCHEMBL6413874 | 0.82 | CHRM3 (0.37) | PPARGPPARAKCNH2CHRM2CHRM4 | |
| SCHEMBL12416119 | 0.80 | ALDH1A1 (0.41) | RAB9AMEN1ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL10025296 | 0.79 | CYP1A2 (0.37) | HRH3PPARGPPARAFPR2PROKR1 | |
| SCHEMBL8278753 | 0.75 | HRH3 (0.40) | HRH3PPARGPPARAFPR2PROKR1 | |
| SCHEMBL14592054 | 0.75 | PPARG (0.40) | HRH3PPARGPPARAFPR2PROKR1 | |
| SCHEMBL13017370 | 0.75 | CHRM2 (0.42) | HRH3KCNH2CHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140056847-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-27 | — | — | US | disclosed |
| US-20130177531-A1 | Inhibitors of Serine Proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-11 | — | — | US | disclosed |
| US-20110171175-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110171175-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-14 | — | — | US | disclosed |
| US-20070105781-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171175-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SERPINB1, PRSS3 | HRH3 2032/4885PPARG 4844/4885PPARA 4798/4885 |
| US-20140056847-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SERPINB1, PRSS3 | HRH3 2032/4885PPARG 4844/4885PPARA 4798/4885 |
| US-20130177531-A1 | Inhibitors of Serine Proteases | PRSS1, SERPINB1, PRSS3 | HRH3 2032/4885PPARG 4844/4885PPARA 4798/4885 |
| US-20070105781-A1 | Inhibitors of serine proteases | PRSS1, SERPINB1, PRSS3 | HRH3 1918/4885PPARG 4843/4885PPARA 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.